BAM
ANVS icon

Blueshift Asset Management’s Annovis Bio ANVS Stock Holding History

Blueshift Asset Management’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16,418
Closed -$289K – 807
2021
Q4 		$289K Buy
+16,418
New +$423K 0.03% 637

Other funds holding ANVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WFAG
Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Blueshift Asset Management's ANVS Position: Q1 2022 in Review

Blueshift Asset Management sold out of Annovis Bio (ANVS) in Q1 2022, closing a stake of 16,418 shares — an estimated $289K sold.

Blueshift Asset Management first reported a position in ANVS in Q4 2021 and held it in 1 quarter. The position peaked at $289K in Q4 2021. 24 funds tracked by Wall St. Rank hold ANVS as of Q1 2022.

  • Blueshift Asset Management reported no remaining Annovis Bio position as of Q1 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 16,418 Annovis Bio shares in Q1 2022, an estimated $289K.
  • Blueshift Asset Management first reported a position in Annovis Bio in Q4 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Annovis Bio position peaked at $289K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2022.

Based on Blueshift Asset Management's 13F filing for Q1 2022, filed 12 May 2022.